Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPSTONE: Phase III study of rVA576 plus standard of care in PNH
2017-003847-39Phase 3Completed
- Sponsor
- Akari Therapeutics
- Start
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing rVA576 plus standard of care with Standard of care (2 arms). Primary endpoint: Haemoglobin stabilisation rate. Started Jan 2018; status: completed.
02
Drugs
nomacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2017-003847-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003847-39.